Healthcare
Latest Healthcare News
View MoreLatest Healthcare Analysis
View MoreSign-Ups For Novo Nordisk's Weight Loss Drug Soar In US
Novo Nordisk's weight loss drug Wegovy experiences booming sign-ups in the US, while facing pricing pressures and emerging competition.
Biogen Tops Q1 Estimates with Alzheimer's Boost
Dive into Biogen's impressive Q1 earnings, featuring an EPS beat and significant LEQEMBI sales growth. Explore what these results mean for the...
Contineum Therapeutics Raises $110 Million in Successful IPO
Contineum Therapeutics' IPO success reflects investor confidence in their innovative therapies for neuroscience, inflammation, and immunology.
Johnson & Johnson (JNJ) Acquires Shockwave Medical (SWAV) for $13.1B
J&J acquires Shockwave Medical for $13.1B, bolstering its medical device portfolio and positioning retail investors for potential growth in the...
Top Picks
View MoreTop Growth Stocks Q2 2022
Growth investing tends to be a medium to long-term investing strategy. Investors looking for growth stocks seek companies that appear to have a...
Top Growth Stocks Q1 2022
Growth investing tends to be a medium to long term investing strategy. Investors looking for growth stocks seek companies that appear to have a...
Top Momentum Stocks Q1 2022
Momentum investing tends to be a short-term investing strategy. Investors looking to buy shares in a stock look for signs of upward momentum and...
Q4 2021 Top Healthcare stocks to consider
Healthcare can be a lucrative investment area, but it's also a challenging sector to invest in. Here are some top health stocks in momentum, growth...
Press Releases
View MoreCardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx™ for Recurrent Pericarditis
Toronto, ON – February 21, 2024 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences...
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
Designation Based on Pre-clinical Data and Initial Clinical Data from the Company’s MAvERIC-Pilot Phase II Study
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the research...
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
Toronto, ON – November 1, 2023 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences...